Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma

Bruce G. Redman, Gilda G. Hillman, Lawrence Flaherty, Jeffrey Forman, B. Dezső, Gabriel P. Haas

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We have previously demonstrated that local tumor irradiation effectively enhanced the therapeutic effect of interleukin 2 (IL-2) therapy in an experimental murine renal adenocarcinoma model. Based on these preclinical studies, we have designed and initiated a Phase II trial of irradiation combined with IL-2 for the treatment of metastatic renal cell carcinoma. Patients received 800 cGy to the primary or metastatic lesion on days 1 and 15 followed by IL-2 (600,000 IU/kg i.v.) every 8 h on days 4-8 and 18-22. Sixteen patients were entered; all completed treatment and are therefore evaluable for toxicity and response. Two partial remissions were seen for a response rate of 12.5% (95% confidence interval, 0-28.7). There was no increase in toxicity over that which is anticipated from IL-2 alone. The antitumor activity seen in this trial is consistent with what would be expected from high-dose IL-2 alone.

Original languageEnglish
Pages (from-to)283-286
Number of pages4
JournalClinical Cancer Research
Volume4
Issue number2
Publication statusPublished - Feb 1998

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Radiation
Therapeutics
Investigational Therapies
Therapeutic Uses
Confidence Intervals
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. / Redman, Bruce G.; Hillman, Gilda G.; Flaherty, Lawrence; Forman, Jeffrey; Dezső, B.; Haas, Gabriel P.

In: Clinical Cancer Research, Vol. 4, No. 2, 02.1998, p. 283-286.

Research output: Contribution to journalArticle

Redman, Bruce G. ; Hillman, Gilda G. ; Flaherty, Lawrence ; Forman, Jeffrey ; Dezső, B. ; Haas, Gabriel P. / Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 2. pp. 283-286.
@article{ab0fdab1e9494c7db5f120ad9b5f8fd3,
title = "Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma",
abstract = "We have previously demonstrated that local tumor irradiation effectively enhanced the therapeutic effect of interleukin 2 (IL-2) therapy in an experimental murine renal adenocarcinoma model. Based on these preclinical studies, we have designed and initiated a Phase II trial of irradiation combined with IL-2 for the treatment of metastatic renal cell carcinoma. Patients received 800 cGy to the primary or metastatic lesion on days 1 and 15 followed by IL-2 (600,000 IU/kg i.v.) every 8 h on days 4-8 and 18-22. Sixteen patients were entered; all completed treatment and are therefore evaluable for toxicity and response. Two partial remissions were seen for a response rate of 12.5{\%} (95{\%} confidence interval, 0-28.7). There was no increase in toxicity over that which is anticipated from IL-2 alone. The antitumor activity seen in this trial is consistent with what would be expected from high-dose IL-2 alone.",
author = "Redman, {Bruce G.} and Hillman, {Gilda G.} and Lawrence Flaherty and Jeffrey Forman and B. Dezső and Haas, {Gabriel P.}",
year = "1998",
month = "2",
language = "English",
volume = "4",
pages = "283--286",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma

AU - Redman, Bruce G.

AU - Hillman, Gilda G.

AU - Flaherty, Lawrence

AU - Forman, Jeffrey

AU - Dezső, B.

AU - Haas, Gabriel P.

PY - 1998/2

Y1 - 1998/2

N2 - We have previously demonstrated that local tumor irradiation effectively enhanced the therapeutic effect of interleukin 2 (IL-2) therapy in an experimental murine renal adenocarcinoma model. Based on these preclinical studies, we have designed and initiated a Phase II trial of irradiation combined with IL-2 for the treatment of metastatic renal cell carcinoma. Patients received 800 cGy to the primary or metastatic lesion on days 1 and 15 followed by IL-2 (600,000 IU/kg i.v.) every 8 h on days 4-8 and 18-22. Sixteen patients were entered; all completed treatment and are therefore evaluable for toxicity and response. Two partial remissions were seen for a response rate of 12.5% (95% confidence interval, 0-28.7). There was no increase in toxicity over that which is anticipated from IL-2 alone. The antitumor activity seen in this trial is consistent with what would be expected from high-dose IL-2 alone.

AB - We have previously demonstrated that local tumor irradiation effectively enhanced the therapeutic effect of interleukin 2 (IL-2) therapy in an experimental murine renal adenocarcinoma model. Based on these preclinical studies, we have designed and initiated a Phase II trial of irradiation combined with IL-2 for the treatment of metastatic renal cell carcinoma. Patients received 800 cGy to the primary or metastatic lesion on days 1 and 15 followed by IL-2 (600,000 IU/kg i.v.) every 8 h on days 4-8 and 18-22. Sixteen patients were entered; all completed treatment and are therefore evaluable for toxicity and response. Two partial remissions were seen for a response rate of 12.5% (95% confidence interval, 0-28.7). There was no increase in toxicity over that which is anticipated from IL-2 alone. The antitumor activity seen in this trial is consistent with what would be expected from high-dose IL-2 alone.

UR - http://www.scopus.com/inward/record.url?scp=0031913708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031913708&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 283

EP - 286

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -